Four biotechs and a Matthew Roden-led SPAC price IPOs, raising a combined $528M
Four more biotechs and a SPAC led by Bristol Myers Squibb vet Matthew Roden have priced IPOs, closing out another busy week on Wall Street.
Together, Praxis Precision Medicines, Tarsus Pharmaceuticals, Aligos Therapeutics, Kiromic BioPharma and Turmeric Acquisition — MPM’s blank check company — have raised $528 million on their public debuts.
Praxis Precision Medicines burst out of stealth mode with $100 million in May, quickly sweeping up another $110 million in July. And on Thursday, it raised $190 million — nearly double its original goal — in an upsized IPO. The Cambridge, MA-based biotech $PRAX offered 10 million shares at $19 apiece, up from its initial offer of 7.4 million shares at a $17 to $18 range.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
